Stocks and Investing Stocks and Investing
Tue, October 1, 2019
Mon, September 30, 2019
Fri, September 27, 2019

Joel Beatty Maintained (SRPT) at Strong Buy with Decreased Target to $180 on, Sep 27th, 2019


Published on 2024-10-26 16:30:28 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $185 to $180 on, Sep 27th, 2019.

Joel has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Joel


  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $201 on, Tuesday, August 20th, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $220 on, Tuesday, July 9th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019

Contributing Sources